AKT1 and cancer: The first group consists of cancer cells whose drug resistance can be overcome by exposing the cells to GCs in combination with drugs that target protein kinases such as Akt, mTOR, Src, ALK, and/or BCR, or drugs antagonizing Bcl-2, Bcl-XL, Mcl-1, c-Myc, or Notch.